New drugs for therapy of AML

This publication has 15 references indexed in Scilit:

• Comparison of idarubicin + ara-C–, fludarabine + ara-C–, and topotecan + ara-C–based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts
  Blood, 2001
• Enhanced ceramide generation and induction of apoptosis in human leukemia cells exposed to DT388–granulocyte-macrophage colony-stimulating factor (GM-CSF), a truncated diphtheria toxin fused to human GM-CSF
  Blood, 2001
• Antibody Response to DT–GM, a Novel Fusion Toxin Consisting of a Truncated Diphtheria Toxin (DT) Linked to Human Granulocyte–Macrophage Colony Stimulating Factor (GM), during a Phase I Trial of Patients with Relapsed or Refractory Acute Myeloid Leukemia
  Clinical Immunology, 2001
• Mylotarg? (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation
  Cancer, 2001
• Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse
  Journal of Clinical Oncology, 2001
• High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia
  Cancer, 2001
• Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial
  Blood, 2001
• Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia
  Blood, 2000
• RASand Leukemia: From Basic Mechanisms to Gene-Directed Therapy
  Journal of Clinical Oncology, 1999
• A bayesian strategy for screening cancer treatments prior to phase ii clinical evaluation
  Statistics in Medicine, 1993